OXFORD, UK - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company, has announced the successful outcomes of a clinical study for its EpiSwitch® Colorectal No-Stool Test (NST), which has been ...
The existing prediction models for severe complications of preeclampsia are most accurate only in the two days after hospital ...